EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
F Skoulidis, JV Heymach - Nature Reviews Cancer, 2019 - nature.com
The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …
[HTML][HTML] Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have not
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors
HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers.
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug …
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug …
Understanding and targeting resistance mechanisms in NSCLC
J Rotow, TG Bivona - Nature Reviews Cancer, 2017 - nature.com
The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
Clinical cancer genomic profiling
D Chakravarty, DB Solit - Nature Reviews Genetics, 2021 - nature.com
Technological innovation and rapid reduction in sequencing costs have enabled the
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …
[HTML][HTML] Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 …
M Riudavets, I Sullivan, P Abdayem, D Planchard - ESMO open, 2021 - Elsevier
Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …
Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma,
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
[HTML][HTML] Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial
Purpose Human epidermal growth factor receptor 2 (HER2, ERBB2)–activating mutations
occur in 2% of lung cancers. We assessed the activity of ado-trastuzumab emtansine, a …
occur in 2% of lung cancers. We assessed the activity of ado-trastuzumab emtansine, a …
[HTML][HTML] Emerging evidence and treatment paradigm of non-small cell lung cancer
SYM Liu, MM Zheng, Y Pan, SY Liu, Y Li… - Journal of hematology & …, 2023 - Springer
Research on biomarker-driven therapy and immune check-point blockade in non-small cell
lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also …
lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also …